Why is Moderna stock surging today?

Moderna's stock price skyrocketed by 9.3% in early trading today, climbing to $168.36, as investors continue to pour money into the Cambridge-based biotech company. This surge is powered by a groundbreaking cancer vaccine that has transformed the company's long-term strategy. The catalyst for this growth originated from a study involving Moderna and Merck, which showed that combining Moderna's personalized cancer vaccine with Merck's Keytruda led to significantly better outcomes for high-risk melanoma patients.

This result is seen as the first-ever Phase 3 success for both a personalized neoantigen vaccine and any mRNA-based cancer treatment. The positive outlook has received support from several analysts, with Argus upgrading Moderna to Buy and setting a $180 price target, while Bank of America also upgraded the stock and increased its price target.

A recent $2.6 billion convertible note offering provided the company with additional resources to further its oncology efforts. However, not everyone is optimistic, with Rothschild & Co. downgrading the stock to Sell and Evercore ISI maintaining a Hold rating. The overall market sentiment is supportive, with major indices rising and creating a favorable environment for high-momentum growth stocks like biotech.

Morgan Stanley's reassurance that negative data from BioNTech's colorectal cancer program does not impact Moderna's mRNA oncology platform has helped protect the company from competition. As a result, Moderna's oncology pipeline continues to be re-rated, driven by a once-in-a-generation clinical milestone and multiple analyst upgrades, leading the stock toward its 52-week high of $176.66.